Compare Stocks: GLASF, ABLYF, SNPHY, and ACBFF

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABLYF Ablynx	$50.63	$50.63	$12.50 ▼ $55.04	$3.81B	1.99	5,063 shs	N/A
ACBFF Aurora Cannabis	$3.83 +0.3%	$3.34	$2.20 ▼ $12.53	$3.68B	N/A	4.22 million shs	582,429 shs
GLASF Glass House Brands	C$12.34	C$12.34	C$4.55 ▼ C$13.93	C$990.56M	N/A	219,805 shs	N/A
SNPHY Santen Pharmaceutical	$11.44 +6.9%	$12.02	$9.22 ▼ $13.93	$3.45B	N/A	1,469 shs	1,523 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABLYF Ablynx	0.00%	0.00%	0.00%	0.00%	0.00%
ACBFF Aurora Cannabis	+2.41%	-1.29%	+4.08%	+31.16%	-23.40%
GLASF Glass House Brands	0.00%	0.00%	0.00%	-9.14%	+72.88%
SNPHY Santen Pharmaceutical	+6.92%	+4.76%	-5.18%	-2.83%	+5.63%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABLYF Ablynx	$50.63	$50.63	$12.50 ▼ $55.04	$3.81B	1.99	5,063 shs	N/A
ACBFF Aurora Cannabis	$3.83 +0.3%	$3.34	$2.20 ▼ $12.53	$3.68B	N/A	4.22 million shs	582,429 shs
GLASF Glass House Brands	C$12.34	C$12.34	C$4.55 ▼ C$13.93	C$990.56M	N/A	219,805 shs	N/A
SNPHY Santen Pharmaceutical	$11.44 +6.9%	$12.02	$9.22 ▼ $13.93	$3.45B	N/A	1,469 shs	1,523 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABLYF Ablynx	0.00%	0.00%	0.00%	0.00%	0.00%
ACBFF Aurora Cannabis	+2.41%	-1.29%	+4.08%	+31.16%	-23.40%
GLASF Glass House Brands	0.00%	0.00%	0.00%	-9.14%	+72.88%
SNPHY Santen Pharmaceutical	+6.92%	+4.76%	-5.18%	-2.83%	+5.63%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABLYF Ablynx	0.00	N/A	N/A	N/A
ACBFF Aurora Cannabis	0.00	N/A	N/A	N/A
GLASF Glass House Brands	2.00	Hold	N/A	N/A
SNPHY Santen Pharmaceutical	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABLYF Ablynx	$62.73M	60.74	N/A	N/A	$2.71 per share	18.68
ACBFF Aurora Cannabis	N/A	N/A	N/A	N/A	N/A	N/A
GLASF Glass House Brands	N/A	N/A	N/A	N/A	N/A	N/A
SNPHY Santen Pharmaceutical	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABLYF Ablynx	-$122.67M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ACBFF Aurora Cannabis	N/A	$0.12	31.92	N/A	N/A	N/A	N/A	N/A	N/A
GLASF Glass House Brands	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SNPHY Santen Pharmaceutical	N/A	N/A	N/A	12.04	N/A	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABLYF Ablynx	N/A	N/A	N/A	N/A	N/A
ACBFF Aurora Cannabis	N/A	N/A	N/A	N/A	N/A
GLASF Glass House Brands	N/A	N/A	N/A	N/A	N/A
SNPHY Santen Pharmaceutical	$0.14	1.22%	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABLYF Ablynx	N/A
ACBFF Aurora Cannabis	N/A
GLASF Glass House Brands	N/A
SNPHY Santen Pharmaceutical	N/A

Insider Ownership

Company	Insider Ownership
ABLYF Ablynx	N/A
ACBFF Aurora Cannabis	N/A
GLASF Glass House Brands	N/A
SNPHY Santen Pharmaceutical	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABLYF Ablynx	N/A	75.25 million	N/A	Not Optionable
ACBFF Aurora Cannabis	1,340	960.96 million	N/A	Not Optionable
GLASF Glass House Brands	362	80.27 million	N/A	Not Optionable
SNPHY Santen Pharmaceutical	4,144	322.29 million	N/A	Not Optionable

GLASF, ABLYF, SNPHY, and ACBFF Headlines

Recent News About These Companies

Santen Pharmaceutical Co Stock Price History

September 3, 2026 | investing.com

Santen Pharmaceutical Co., Ltd. GAAP EPS of ¥22.30, revenue of ¥68.9B

August 6, 2026 | seekingalpha.com

Santen boosts profits in Q1 and maintains upbeat full-year outlook

August 6, 2026 | tipranks.com

Santen Pharmaceutical Co Ltd ADR SNPHY

May 14, 2026 | morningstar.comM

Santen Pharmaceutical Co., - Depositary Receipt (SNPHY) Price Target Decreased by 10.74% to 13.32

November 9, 2025 | msn.com

Santen Pharmaceutical 1H Net Y13.94B Vs Net Y18.77B

November 6, 2025 | marketwatch.com

Santen Pharmaceutical to Cancel 19.8 Million Treasury Shares

November 6, 2025 | tipranks.com

Santen Pharmaceutical Updates on Share Buyback Progress

November 4, 2025 | tipranks.com

Santen Pharmaceutical Reports Progress on Share Buyback Initiative

October 1, 2025 | tipranks.com

Santen Pharmaceutical Updates on Share Buyback Progress

September 1, 2025 | tipranks.com

Santen and RemeGen sign licence deal for retinal disease injection

August 19, 2025 | msn.com

Santen Pharmaceutical Co (SNPHY) - Investing.com UK

August 8, 2025 | uk.investing.com

Santen Pharmaceutical Updates on Share Buyback Progress

July 1, 2025 | tipranks.com

Santen Pharmaceutical FY Net Y36.26B Vs Net Y26.64B

May 13, 2025 | marketwatch.com

China’s NMPA authorises Santen’s glaucoma treatment application

April 7, 2025 | msn.com

Santen Pharmaceutical to Cancel 5 Million Treasury Shares

February 6, 2025 | tipranks.com

Santen Pharmaceutical Co. Revises Year-End Dividend Forecast

February 6, 2025 | tipranks.com

Santen Pharmaceutical Announces Share Buyback Plan

November 8, 2024 | markets.businessinsider.com

Santen Pharmaceutical Co., Ltd. GAAP EPS of Yen 27.85, revenue of Yen 72.34B

August 6, 2024 | msn.com

Here's what to expect from Santen Pharmaceutical's earnings report

August 6, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLASF, ABLYF, SNPHY, and ACBFF Company Descriptions

Ablynx OTCMKTS:ABLYF

$50.63 0.00 (0.00%)

As of 04/30/2019

Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.

Aurora Cannabis OTCMKTS:ACBFF

$3.83 +0.01 (+0.26%)

As of 09/16/2026

Aurora Cannabis Inc is a Canada-based company engaged in the production and distribution of medical cannabis. The Company is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, home cultivation, wholesale and retail distribution. The Company's purpose-built facilities, which integrate technologies across all processes, are defined by automation and customization. The Company has a funded capacity of more than 500,000 kilograms per year, as well as sales and operations in more than 10 countries worldwide.

Glass House Brands OTCMKTS:GLASF

C$12.34 0.00 (0.00%)

As of 09/16/2026

Glass House Brands Inc., together with its subsidiaries, operates as an integrated cannabis company in the United States. The company operates in three segments: Retail; Wholesale Biomass; and Cannabis-Related Consumer Packaged Goods. It cultivates, manufactures, and distributes cannabis bulk flowers and trims to wholesalers; and consumer packaged goods to third-party retail stores in California. The company also owns and operates retail cannabis stores. In addition, it offers raw cannabis, cannabis oil, and cannabis consumer goods; edibles; flower jars and bags; single, multi-pack, and infused pre-rolls; tinctures; biomass for distributors; and online payment processing, in-store pickup and home delivery services for adult-use and medicinal-use customers. The company offers its cannabis products under the Glass House Farms, FIELD, Forbidden Flowers, PLUS, Mama Sue, Allswell, and REEFORM brand names. Glass House Brands Inc. was founded in 2015 and is headquartered in Long Beach, California.

Santen Pharmaceutical OTCMKTS:SNPHY

$11.44 +0.74 (+6.92%)

As of 09/17/2026 03:46 PM Eastern

Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in phase 3 of clinical trials; and latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative which is filed for marketing approval for the treatment of glaucoma and ocular hypertension. In addition, it provides cyclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis; and diquafosol sodium for dry eye treatment. Further, the company develops olodaterol hydrochloride, a ß2 receptor agonist that is in phase 1/2a for the treatment of A dry eye treatment dry eye; sirolimus, an ophthalmic suspension which is in phase 2a for the treatment of 4 Fuchs endothelial corneal dystrophy and meibomian gland dysfunction; epinastine hydrochloride, a histamine H1 receptor antagonist filed for marketing approval for the treatment of allergic conjunctivitis; atropine sulfate, a non-selective muscarinic antagonist that is in phase 2/3 clinical trials for myopia treatment; and AFDX0250BS, an selective muscarinic M2 antagonist which is in phase 2a for the treatment of myopia. Additionally, it offers ursodeoxycholic acid that is in phase 2a of clinical trial for the treatment of presbyopia; and oxymetazoline hydrochloride, a direct-acting alpha adrenergic receptor agonist which is in phase 3 for treatment of ptosis. The company was founded in 1890 and is headquartered in Osaka, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Compare Profitability & Earnings

Compare Dividends

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GLASF, ABLYF, SNPHY, and ACBFF Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLASF, ABLYF, SNPHY, and ACBFF Company Descriptions

Ablynx OTCMKTS:ABLYF

Aurora Cannabis OTCMKTS:ACBFF

Glass House Brands OTCMKTS:GLASF

Santen Pharmaceutical OTCMKTS:SNPHY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Compare Profitability & Earnings

Compare Dividends

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GLASF, ABLYF, SNPHY, and ACBFF Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLASF, ABLYF, SNPHY, and ACBFF Company Descriptions

Ablynx OTCMKTS:ABLYF

Aurora Cannabis OTCMKTS:ACBFF

Glass House Brands OTCMKTS:GLASF

Santen Pharmaceutical OTCMKTS:SNPHY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools